• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by MoonLake Immunotherapeutics

    3/31/23 4:23:05 PM ET
    $MLTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MLTX alert in real time by email
    SC 13G 1 sc13g.htm
     
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
         
         
         
     
    SCHEDULE 13G
     
     
     
    Under the Securities Exchange Act of 1934
     
     
     
    (Amendment No.  __)*
     
         
     
    MoonLake Immunotherapeutics
     
     
    (Name of Issuer)
     
         
     
    Class A Ordinary Shares
     
     
    (Title of Class of Securities)
     

     
    61559X104
     
     
    (CUSIP Number)
     

     
    December 31, 2022†
     
     
    (Date of Event which Requires Filing of this Statement)
     


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    [x]
    Rule 13d-1(b)
     
    [ ]
    Rule 13d-1(c)
     
    [ ]
    Rule 13d-1(d)
     





    ___________________________________
    *  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
     
    †  Beneficial ownership information reported herein is as of the date of filing.
     
    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).
     

    CUSIP NO.
    61559X104
     
    1
    Names of Reporting Persons.
     
    Bihua Chen
     
    2
    Check the Appropriate Box if a Member of a Group (See Instructions)
     
    (a) [ ]
     
    (b) [x]
    3
    SEC Use Only
    4
    Citizenship or Place of Organization.
     
    United States
    Number
    of Shares
    Beneficially
    Owned by
    Each
    Reporting
    Person With
    5 Sole Voting Power
     
    0 shares
    6 Shared Voting Power
     
    6,892,100 shares

    Refer to Item 4 below.
    7 Sole Dispositive Power
     
    0 shares
    8 Shared Dispositive Power
     
    6,892,100 shares

    Refer to Item 4 below.
    9
    Aggregate Amount Beneficially Owned by Each Reporting Person
     
    6,892,100 shares

    Refer to Item 4 below.
    10
    Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
        [ ] N/A
    11
    Percent of Class Represented by Amount in Row (9)*
     
    17.60%
     
    Refer to Item 4 below.
    12
    Type of Reporting Person (See Instructions)
     
    HC, IN (Control Person, Individual)

    CUSIP NO.
    61559X104
     
    Item 1.
     
     
    (a)
    Name of Issuer
         
       
    MoonLake Immunotherapeutics
     
     
    (b)
    Address of Issuer’s Principal Executive Offices
       
     
    Dorfstrasse 29, Zug, Switzerland 6300

    Item 2.
     
     
    (a)
    Name of Person Filing
         
       
    Bihua Chen
     
     
    (b)
    Address of Principal Business Office or, if none, Residence
         
       
    200 Clarendon Street, 52nd Floor
    Boston, MA 02116
     
     
    (c)
    Citizenship
       
     
    United States
     
     
    (d)
    Title of Class of Securities
         
       
    Class A Ordinary Shares
     
     
    (e)
    CUSIP Number
       
    61559X104


    CUSIP NO.
    61559X104

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
     
     
    (a)
    [ ]
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     
    (b)
    [ ]
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

     
    (c)
    [ ]
    Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c).

     
    (d)
    [ ]
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8).

     
    (e)
    [ ]
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

     
    (f)
    [ ]
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);

     
    (g)
    [X]
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

     
    (h)
    [ ]
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

     
    (i)
    [ ]
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

     
    (j)
    [ ]
    A non-U.S. institution in accordance with §240.13d–1(b)(1)(ii)(J);

     
    (k)
    [ ]
    Group, in accordance with §240.13d-1(b)(1)(ii)(K).

    Item 4.
    Ownership***
     
    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
     

    (a)
    Amount Beneficially Owned***

    The information set forth in Row 9 on the cover page for the Reporting Person is hereby incorporated by reference into this Item 4(a).


    (b)
    Percent of Class***

    The information set forth in Row 11 on the cover page for the Reporting Person is hereby incorporated by reference into this Item 4(b).


    (c)
    Number of shares as to which such person has: ***


    (i)
    sole power to vote or to direct the vote


    (ii)
    shared power to vote or to direct the vote


    (iii)
    sole power to dispose or to direct the disposition of


    (iv)
    shared power to dispose or to direct the disposition of


    CUSIP NO.
    61559X104
     
    The information set forth in Rows 5 through 8 on the cover page for the Reporting Person is hereby incorporated by reference into this Item 4(c).
     
    *** Shares reported herein represent shares held for the benefit of investment funds for which Cormorant Asset Management, LP serves as the investment manager and for Helix Holdings LLC.  Bihua Chen serves as the general partner of Cormorant Asset Management, LP and as manager of Helix Holdings LLC.  The Reporting Person disclaims beneficial ownership of the shares reported herein except to the extent of her pecuniary interest therein.
     
    The percentages reported herein with respect to the Reporting Person’s holdings are calculated based upon a statement in the Issuer’s Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on March 20, 2023, that there were 39,154,203 Class A Ordinary Shares of the Issuer outstanding as of March 1, 2023.

    Item 5.
    Ownership of Five Percent or Less of a Class
     
    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following [  ].
     
    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person

    Each of Cormorant Asset Management, LP, on behalf of the investment funds for which it serves as investment manager, and Helix Holdings LLC has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5% of the Class A Ordinary Shares.
     
    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    Not applicable.
     
    Item 8.
    Identification and Classification of Members of the Group

    Not applicable.
     
    Item 9.
    Notice of Dissolution of Group

    Not applicable.
     
    Item 10.
    Certification
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.
     
    Exhibits
    Exhibit
     
    Not applicable.
     

    CUSIP NO.
    61559X104
     
    SIGNATURE
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.
     
    March 31, 2023
     

    /s/ Bihua Chen
    Bihua Chen








    Get the next $MLTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MLTX

    DatePrice TargetRatingAnalyst
    5/19/2025$61.00Peer Perform → Outperform
    Wolfe Research
    3/18/2025$67.00Outperform
    RBC Capital Mkts
    1/17/2025$62.00 → $82.00Neutral → Buy
    Goldman
    11/5/2024$92.00 → $73.00Outperform
    Wedbush
    8/26/2024Outperform → Peer Perform
    Wolfe Research
    6/25/2024$104.00Outperform
    Oppenheimer
    4/2/2024$62.00Neutral
    Goldman
    2/15/2024$77.00Outperform
    Wolfe Research
    More analyst ratings

    $MLTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29

      MoonLake Immunotherapeutics to host a Capital Markets Day on Tuesday, April 29 Zug, Switzerland, April 25, 2025 – MoonLake Immunotherapeutics (NASDAQ:MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, will host a virtual Capital Markets Day for investors and analysts on Tuesday, April 29, 2025. The event will highlight recent financial and clinical milestones and provide future strategic updates. The webcast, streamed live from New York, will start at 8:30 AM EST (2:30 PM CET) and is expected to last one hour. A recording will be made available post event. Webcast Access: https://edge.media-server.com/mmc/p/sgz7i4x9 MoonLake'

      4/25/25 4:05:00 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates

      Agreement with Hercules Capital significantly increases financial and operational strength, provides up to $500 million in capital with no dilution to shareholders, an attractive cost of capital and low operational and strategic incumbrances, and sets a new standard for the quantum of a nondilutive facility for a development-stage therapeutics company.Facility adds to the $448 million cash position disclosed in previously filed 10-K and provides funding for the next steps of the Company's growth, including the expected launch of sonelokimab in 2027, additional clinical trials and further investments for growth.The Company will hold an in-person and virtual Capital Markets Update on Tuesday,

      4/3/25 7:00:00 AM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Financials

    Live finance-specific insights

    See more
    • MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports First Quarter 2025 Financial Results and Provides a Business Update Continued to make significant progress with the development of the Nanobody® sonelokimab across portfolio of indications, including Phase 3 studies in hidradenitis suppurativa (HS), psoriatic Arthritis (PsA) and adolescent HS, as well as Phase 2 studies in palmoplantar pustulosis (PPP) and axial spondyloarthritis (axSpA)Announced completion of enrollment of patients in the Phase 3 program in HS (the VELA program) and disclosed baseline characteristics, replicating the Phase 2 MIRA trialPresented an interim readout of the Phase 2 LEDA study in PPP, highlighting the potential of sonelokimab

      5/12/25 4:00:00 PM ET
      $HTGC
      $MLTX
      Investment Managers
      Finance
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update

      Initiated the Phase 3 VELA program of the Nanobody® sonelokimab in patients with moderate-to-severe hidradenitis suppurativa (HS) and the Phase 3 IZAR program in patients with active psoriatic arthritis (PsA) following positive FDA and EMA regulatory feedback, continuing to support a potential best-in-class profile across two key indicationsInitiated three new trials in the beginning of 2025 with the Nanobody® sonelokimab: Phase 3 VELA-TEEN trial in adolescent hidradenitis suppurativa (HS), Phase 2 LEDA trial in palmoplantar pustulosis (PPP) and Phase 2 S-OLARIS trial in axial spondyloarthritis (axSpA)Signed a three-year technology partnership with Komodo Health to advance research on inflam

      2/26/25 7:00:00 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update

      MoonLake Immunotherapeutics Reports Third Quarter 2024 Financial Results and Provides a Business Update Ended the third quarter with $493.9 million in cash, cash equivalents and short-term marketable debt securities, expected to support a roadmap rich in potential catalysts and a cash runway to the end of 2026Strong market performance of other IL-17 inhibitors in hidradenitis suppurativa (HS) and other inflammatory indications validating large market opportunity for sonelokimabPhase 3 clinical program in HS is progressing as per plan with primary endpoint readout anticipated as of mid-2025Preparations for Phase 3 clinical program in psoriatic arthritis (PsA) completed with patient enrollmen

      11/7/24 7:00:00 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MLTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4 filed by Director Bvf Partners L P/Il

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      6/9/25 7:16:08 PM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Sturge Simon

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      6/9/25 9:08:48 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Loy Spike

      4 - MoonLake Immunotherapeutics (0001821586) (Issuer)

      6/9/25 9:07:53 AM ET
      $MLTX
      Biotechnology: Pharmaceutical Preparations
      Health Care